Mylan to handle some of Gilead's branded drugs in tricky Indian market

Gilead Sciences ($GILD) and Mylan ($MYL) have for years had a deal for Mylan to make generic versions of some of Gilead's HIV drugs in markets around the world. Now Mylan will take over distribution of Gilead's branded products in India, a country where high-cost meds have sometimes met patent challenges. Mylan announced today it would make and distribute in India Gilead's HIV drugs Viread, Truvada and Stribild, as well as infection fighter AmBisome and Viread for treating hepatitis B. The often high prices for Gilead's drugs has produced backlash from activists who say it puts them out of the reach of people in developing countries. It has worked with Mylan to make cheaper versions of some of those as a way to address those concerns. "We have established an excellent working relationship with Mylan over the past few years and believe that their operations in India will allow the company to best serve the needs of patients in that country," Gilead Executive VP Gregg H. Alton said in a statement. Release | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.